VRTX Stock Analysis: Vertex Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 130.789m USD | 12M Return: 31.3% | US92532F1003 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 483M
Qual. Beats: 0
Rev. Trend: 99.9%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Vertex Pharmaceuticals (NASDAQ: VRTX) is a Boston-based biotechnology company founded in 1989 that develops and commercializes specialty medicines for serious diseases, with a primary focus on cystic fibrosis (CF). Its marketed CF portfolio includes TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, targeting patients across various age groups and genetic mutations.
Beyond CF, Vertex is expanding into adjacent specialty areas. It markets CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia, and JOURNAVX for acute pain. Its pipeline includes candidates in mid- to early-stage trials for Type 1 Diabetes, myotonic dystrophy type 1, APOL1-mediated kidney disease, and autosomal dominant polycystic kidney disease.
As a large-cap biotech, Vertex sells its products through specialty pharmacies, distributors, wholesalers, retail pharmacies, hospitals, and clinics. Specialty biotech business models like Vertexs typically rely on high per-patient pricing for small patient populations and reinvestment of revenue into R&D to expand into new therapeutic areas.
- JOURNAVX launch expands into acute pain market
- CASGEVY adoption drives sickle cell revenue growth
- TRIKAFTA patent expiry risks long-term CF revenue
| Net Income: 4.41b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA -0.72 > 1.0 |
| NWC/Revenue: 68.17% < 20% (prev 55.08%; Δ 13.09% < -1%) |
| CFO/TA 0.16 > 3% & CFO 4.29b > Net Income 4.41b |
| Net Debt (-5.87b) to EBITDA (5.39b): -1.09 < 3 |
| Current Ratio: 3.19 > 1.5 & < 3 |
| Outstanding Shares: last quarter (255.7m) vs 12m ago -1.24% < -2% |
| Gross Margin: 86.04% > 18% (prev 86.11%; Δ -0.07% > 0.5%) |
| Asset Turnover: 49.06% > 50% (prev 47.51%; Δ 1.56% > 0%) |
| Interest Coverage Ratio: 397.1 > 6 (EBIT TTM 5.28b / Interest Expense TTM 13.3m) |
| A: 0.31 (Total Current Assets 12.5b - Total Current Liabilities 3.94b) / Total Assets 27.4b |
| B: 0.57 (Retained Earnings 15.7b / Total Assets 27.4b) |
| C: 0.21 (EBIT TTM 5.28b / Avg Total Assets 25.7b) |
| D: 2.82 (Book Value of Equity 20.2b / Total Liabilities 7.18b) |
| Altman-Z'' = 8.27 = AAA |
| DSRI: 1.02 (Receivables 2.13b/1.89b, Revenue 12.6b/11.4b) |
| GMI: 1.00 (GM 86.11% / 86.04%) |
| AQI: 0.92 (AQ_t 0.42 / AQ_t-1 0.46) |
| SGI: 1.11 (Revenue 12.6b / 11.4b) |
| TATA: 0.00 (NI 4.41b - CFO 4.29b) / TA 27.4b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of September 20, 2026, the stock is trading at USD 508.34 with a total of 2,423,621 shares traded. Over the past week, the price has changed by -1.38%, over one month by -3.76%, over three months by +12.56% and over the past year by +31.32%.
Current recommended Stop Loss: 488.20 (which is 4% or 1.7 ATR below the current price).
Vertex Pharmaceuticals has received a consensus analysts rating of 3.85. Therefore, it is recommended to buy VRTX.
- StrongBuy: 14
- Buy: 4
- Hold: 14
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 569.2 | 12% |
P/E Trailing = 29.8462
P/E Forward = 23.9808
P/S = 10.3972
P/B = 6.4249
P/EG = 1.8863
Revenue TTM = 12.6b USD
EBIT TTM = 5.28b USD
EBITDA TTM = 5.39b USD
Long Term Debt = unknown (none)
Short Term Debt = 82.8m USD (from shortTermDebt, last fiscal year)
Debt = 1.98b USD (from shortLongTermDebtTotal, last quarter) (leases 1.98b already included)
Net Debt = -5.87b USD (calculated: Debt 1.98b - CCE 7.85b)
Enterprise Value = 125b USD (131b + Debt 1.98b - CCE 7.85b)
Interest Coverage Ratio = 397.1 (Ebit TTM 5.28b / Interest Expense TTM 13.3m)
EV/FCF = 32.91x (Enterprise Value 125b / FCF TTM 3.80b)
FCF Yield = 3.04% (FCF TTM 3.80b / Enterprise Value 125b)
FCF Margin = 30.07% (FCF TTM 3.80b / Revenue TTM 12.6b)
Net Margin = 34.89% (Net Income TTM 4.41b / Revenue TTM 12.6b)
Gross Margin = 86.04% ((Revenue TTM 12.6b - Cost of Revenue TTM 1.76b) / Revenue TTM)
Gross Margin QoQ = 85.33% (prev 86.85%)
Tobins Q-Ratio = 4.56 (Enterprise Value 125b / Total Assets 27.4b)
Interest Expense / Debt = 0.67% (Interest Expense 13.3m / Debt 1.98b)
Taxrate = 16.48% (869.3m / 5.27b)
NOPAT = 4.41b (EBIT 5.28b * (1 - 16.48%))
Current Ratio = 3.19 (Total Current Assets 12.5b / Total Current Liabilities 3.94b)
Debt / Equity = 0.10 (Debt 1.98b / totalStockholderEquity, last quarter 20.2b)
Debt / EBITDA = -1.09 (Net Debt -5.87b / EBITDA 5.39b)
Debt / FCF = -1.55 (Net Debt -5.87b / FCF TTM 3.80b)
Total Stockholder Equity = 18.9b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.12% (Net Income 4.41b / Total Assets 27.4b)
RoE = 23.31% (Net Income TTM 4.41b / Total Stockholder Equity 18.9b)
RoCE = 22.49% (EBIT 5.28b / Capital Employed (Total Assets 27.4b - Current Liab 3.94b))
RoIC = 19.23% (NOPAT 4.41b / Invested Capital 22.9b)
WACC = 6.94% (E(131b)/V(133b) * Re(7.04%) + D(1.98b)/V(133b) * Rd(0.67%) * (1-Tc(0.16)))
Discount Rate = 7.04% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -85.31 | Cagr: -0.92%
[DCF] Terminal Value 76.49% ; FCFF base≈3.68b ; Y1≈3.95b ; Y5≈4.79b
[DCF] Fair Price = 313.5 (EV 73.5b - Net Debt -5.87b = Equity 79.4b / Shares 253.3m; r=8.35% [WACC [floored]]; 5y FCF grow 8.47% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.11 | # QB: 0
Revenue Correlation: 99.86 | Revenue CAGR: 10.17% | SUE: 1.55 | # QB: 1
EPS current Quarter (2026-09-30): EPS=-1.74 | Chg30d=-135.40% | Revisions=-13% | Analysts=11
EPS current Year (2026-12-31): EPS=16.02 | Chg30d=-15.90% | Revisions=-13% | GrowthEPS=-12.9% | GrowthRev=+10.4%
EPS next Year (2027-12-31): EPS=20.13 | Chg30d=-7.65% | Revisions=+19% | GrowthEPS=+25.7% | GrowthRev=+9.7%
[Analyst] Revisions Ratio: -2% (up=18, down=19)